Efficacy, safety, and patient-reported outcomes across young to older age groups of patients with HR+/HER2– advanced breast cancer treated with ribociclib plus endocrine therapy in the randomized MONALEESA-2, −3, and −7 trials
European Journal of Cancer · 2025
DOI: 10.1016/j.ejca.2025.115225 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Cancer, 2025. Verfasst von Lowell L Hart und 12 weiteren Autor:innen. Beteiligte Einrichtung: Florida Cancer Specialists, Sarah Cannon Research Institute, Fort Myers, FL, USA; Wake Forest School of Medicine, Winston-Salem, NC, USA. Electronic …. Hauptthemen laut MEDLINE: Breast Neoplasms, Purines, Aminopyridines, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novartis Pharmaceuticals Corporation.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Florida Cancer Specialists, Sarah Cannon Research Institute, Fort Myers, FL, USA; Wake Forest School of Medicine, Winston-Salem, NC, USA. Electronic address: llhart@wakehealth.edu.
- Cancer Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea.
- Dana-Farber Cancer Institute, Boston, MA, USA.
- Institut de Cancérologie de l'Ouest/René Gauducheau Centre de Recherche en Cancérologie, St. Herblain, France.
- Saint Luke's Cancer Institute, Kansas City, MO, USA.
- Breast Unit, Champalimaud Clinical and Research Center/Champalimaud Foundation, Lisbon, Portugal.
Förderung
- Novartis Pharmaceuticals Corporation
Zitieren
APA
Hart, L. L., Im, S. A., Tolaney, S. M., Campone, M., Pluard, T., Sousa, B., Freyer, G., Decker, T., Kalinsky, K., Sopher, G., Gao, M., Hu, H., & Kuemmel, S. (2025). Efficacy, safety, and patient-reported outcomes across young to older age groups of patients with HR+/HER2– advanced breast cancer treated with ribociclib plus endocrine therapy in the randomized MONALEESA-2, −3, and −7 trials. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2025.115225
Vancouver
Hart LL, Im SA, Tolaney SM, Campone M, Pluard T, Sousa B, et al. Efficacy, safety, and patient-reported outcomes across young to older age groups of patients with HR+/HER2– advanced breast cancer treated with ribociclib plus endocrine therapy in the randomized MONALEESA-2, −3, and −7 trials. European Journal of Cancer. 2025. doi:10.1016/j.ejca.2025.115225
BibTeX
@article{Hart2025,
author = {Hart, Lowell L and Im, Seock-Ah and Tolaney, Sara M and Campone, Mario and Pluard, Timothy and Sousa, Berta and Freyer, Gilles and Decker, Thomas and Kalinsky, Kevin and Sopher, Gary and Gao, Melissa and Hu, Huilin and Kuemmel, Sherko},
title = {Efficacy, safety, and patient-reported outcomes across young to older age groups of patients with HR+/HER2– advanced breast cancer treated with ribociclib plus endocrine therapy in the randomized MONALEESA-2, −3, and −7 trials},
journal = {European Journal of Cancer},
year = {2025},
doi = {10.1016/j.ejca.2025.115225}
}
EUVIMED